This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaupel, P. Articles by Harrison, L. Search for Related Content PubMed PubMed Citation Articles by Vaupel, P. Articles by Harrison, L.

Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response

^a Institute of Physiology and Pathophysiology, University of Mainz, Mainz, Germany; ^b Beth Israel Medical Center, New York City, New York, USA

Correspondence: Peter Vaupel, M.D., Dr. Med., M.A., Institute of Physiology and Pathophysiology, University of Mainz, Duesbergweg 6, 55099 Mainz, Germany. Telephone: 49-6131-3925929; Fax: 49-6131-3925774; e-mail: vaupel{at}uni-mainz.de

Hypoxia is a characteristic feature of locally advanced solid tumors resulting from an imbalance between oxygen (O₂) supply and consumption. Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O₂ transport capacity of the blood due to the presence of disease- or treatment-related anemia. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of radiotherapy, some O₂-dependent cytotoxic agents, and photodynamic therapy. Tumor hypoxia can also negatively impact therapeutic outcome by inducing changes in the proteome and genome of neoplastic cells that further survival and malignant progression by enabling the cells to overcome nutritive deprivation or to escape their hostile environment. The selection and clonal expansion of these favorably altered cells further aggravate tumor hypoxia and support a vicious circle of increasing hypoxia and malignant progression while concurrently promoting the development of more treatment-resistant disease. This pattern of malignant progression, coupled with the demonstration of a relationship between falling hemoglobin level and worsening tumor oxygenation, highlights the need for effective treatment of anemia as one approach for correcting anemic hypoxia in tumors, and in so doing, possibly improving therapeutic response.

Key Words. Tumor hypoxia • Causative factors • Cellular response • Malignant progression • Biology • Anemia • Hemoglobin

This article has been cited by other articles:

				D. J. Stewart Foreword--New Directions for Topotecan in Lung Cancer Treatment Oncologist, December 1, 2004; 9(suppl_6): 1 - 3. [Full Text] [PDF]